Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial

Leukemia

Volumn 29, Issue 5, 2015, Pages 1060-1068

  Schetelig, J ^a,b   Schaich, M ^a   Schafer Eckart K ^c   Hanel M ^d   Aulitzky, W E ^e   Einsele, H ^f   Schmitz, N ^g   Rosler W ^h   Stelljes, M ⁱ   Baldus, C D ^j   Ho, A D ^k   Neubauer, A ^l   Serve, H ^m   Mayer, J ⁿ   Berdel, W E ⁱ   Mohr, B ^a   Oelschlagel U ^a   Parmentier, S ^a   Rollig C ^a   Kramer, M ^a   Platzbecker, U ^a   Illmer, T ^a   Thiede, C ^a   Bornhauser M ^a   Ehninger, G ^a   more..

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DKMS Nabelschnurblutbank   (Germany)

^c KLINIKUM NÜRNBERG   (Germany)

^d KLINIKUM CHEMNITZ   (Germany)

^e ROBERT BOSCH HOSPITAL   (Germany)

^f UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^g DEPARTMENT OF CARDIOLOGY   (Germany)

^h UNIVERSITY HOSPITAL ERLANGEN   (Germany)

ⁱ UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l UNIVERSITY HOSPITAL MARBURG   (Germany)

^m UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁿ UNIVERSITY HOSPITAL BRNO   (Czech Republic)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BUSULFAN; CD135 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; MELPHALAN; METHOTREXATE; MITOXANTRONE; FLT3 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HLA TYPING; HUMAN; INCIDENCE; INDUCTION CHEMOTHERAPY; INTENTION TO TREAT ANALYSIS; INTERMEDIATE RISK PATIENT; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIBLING; UNRELATED DONORS; WHOLE BODY RADIATION; ALLELE; ALLOTRANSPLANTATION; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; KAPLAN MEIER METHOD; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ALLELES; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929283886     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.335     Document Type: Article

References (33)

1. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
2. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 2003; 102: 1232-1240.
3. Burnett AK, Wheatley K, Goldstone AH, Stevens R, Hann I, Hills RK. Long-term results of the MRC AML10 trial. Clin Adv Hematol Oncol 2006; 4: 445-451.
4. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109: 3658-3666.
5. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009; 301: 2349-2361.
6. Schetelig J, Bornhauser M, Schmid C, Hertenstein B, Schwerdtfeger R, Martin H et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol 2008; 26: 5183-5191.
7. Gupta V, Tallman MS, He W, Logan BR, Copelan E, Gale RP et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood 2010; 116: 1839-1848.
8. Woolfrey A, Lee SJ, Gooley TA, Malkki M, Martin PJ, Pagel JM et al. HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category. Biol Blood Marrow Transplant 2010; 16: 1382-1387.
9. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 2009; 43: 275-291.
10. Platzbecker U, Thiede C, Freiberg-Richter J, Rollig C, Helwig A, Schakel U et al. Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia. Bone Marrow Transplant 2001; 27: 543-546.
11. Platzbecker U, Thiede C, Fussel M, Geissler G, Illmer T, Mohr B et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 2006; 20: 707-714.
12. Schaich M, Parmentier S, Kramer M, Illmer T, Stolzel F, Rollig C et al. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. J Clin Oncol 2013; 31: 2094-2102.
13. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930.
14. Buchner T, Schlenk RF, Schaich M, Dohner K, Krahl R, Krauter J et al. Acute myeloid leukemia (AML): different treatment strategies versus a common standard arm-combined prospective analysis by the German AML Intergroup. J Clin Oncol 2012; 30: 3604-3610.
15. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
16. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101: 64-70.
17. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-115.
18. Bornhauser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012; 13: 1035-1044.
19. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15: 825-828.
20. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1989; 4: 247-254.
21. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64: 191-199.
22. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med 1984; 3: 35-44.
23. Lown RN, Shaw BE. Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision. Bone Marrow Transplant 2013; 48: 210-219.
24. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013; 31: 1310-1316.
25. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653-660.
26. Eapen M, O'Donnell P, Brunstein CG, Wu J, Barowski K, Mendazibal A et al. Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. Biol Blood Marrow Transplant 2014; 20: 1485-1492.
27. Mantel N, Byar DP. Evaluation of response-time data involving transient states: an illustration using heart-transplant data. Biometrics 1974; 69: 81-86.
28. Burnett AK. Treatment of acute myeloid leukemia: are we making progress? Hematology Am Soc Hematol Educ Program 2012; 2012: 1-6.
29. Craddock C, Labopin M, Pillai S, Finke J, Bunjes D, Greinix H et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011; 25: 808-813.
30. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol 2010; 28: 3730-3738.
31. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
32. Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J et al. High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant 2008; 41: 721-727.
33. Warlick ED, Paulson K, Brazauskas R, Zhong X, Miller AM, Camitta BM et al. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant 2014; 20: 202-208.